

Andrew B Singleton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/290190/publications.pdf>

Version: 2024-02-01

75
papers

21,272
citations

57631

44
h-index

66788

78
g-index

88
all docs

88
docs citations

88
times ranked

24510
citing authors

#	ARTICLE	IF	CITATIONS
1	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. <i>Neuron</i> , 2011, 72, 257-268.	3.8	3,833
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
3	Genome-wide association study reveals genetic risk underlying Parkinson's disease. <i>Nature Genetics</i> , 2009, 41, 1308-1312.	9.4	1,745
4	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014, 46, 989-993.	9.4	1,685
5	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	4.9	1,414
6	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011, 95, 629-635.	2.8	1,278
7	A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. <i>Nature Genetics</i> , 2017, 49, 1511-1516.	9.4	944
8	Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain. <i>PLoS Genetics</i> , 2010, 6, e1000952.	1.5	722
9	The genetic architecture of Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 170-178.	4.9	620
10	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	3.8	517
11	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. <i>PLoS Genetics</i> , 2012, 8, e1002548.	1.5	495
12	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. <i>Nature Neuroscience</i> , 2014, 17, 664-666.	7.1	398
13	Targeting α -synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. <i>Lancet Neurology</i> , The, 2015, 14, 855-866.	4.9	393
14	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016, 98, 500-513.	2.6	333
15	The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
16	Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α -synuclein mechanisms. <i>Movement Disorders</i> , 2019, 34, 866-875.	2.2	258
17	Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. <i>Neurobiology of Disease</i> , 2020, 137, 104782.	2.1	241
18	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	9.4	223

#	ARTICLE	IF	CITATIONS
19	DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. <i>Lancet Neurology</i> , The, 2008, 7, 207-215.	4.9	202
20	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
21	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	4.9	195
22	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	3.9	190
23	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology</i> , The, 2015, 14, 1002-1009.	4.9	179
24	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. <i>Human Molecular Genetics</i> , 2012, 21, 4996-5009.	1.4	176
25	A Genome-Wide Association Study of Depressive Symptoms. <i>Biological Psychiatry</i> , 2013, 73, 667-678.	0.7	149
26	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , 2020, 143, 234-248.	3.7	149
27	A genome-wide association study in multiple system atrophy. <i>Neurology</i> , 2016, 87, 1591-1598.	1.5	139
28	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018, 33, 771-782.	2.2	136
29	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2019, 85, 470-481.	2.8	118
30	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. <i>Neurobiology of Aging</i> , 2017, 57, 247.e9-247.e13.	1.5	108
31	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	2.2	104
32	Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 424-433.	2.2	101
33	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e7-1605.e12.	1.5	96
34	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	4.9	94
35	Parkinson's disease and dementia with Lewy bodies: a difference in dose?. <i>Lancet</i> , The, 2004, 364, 1105-1107.	6.3	80
36	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	1.5	78

#	ARTICLE	IF	CITATIONS
37	Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. <i>Movement Disorders</i> , 2004, 19, 796-800.	2.2	71
38	Genome-Wide Analysis of the Heritability of Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 1123.	4.5	69
39	The Parkinson's Disease <sc>Genome-Wide</sc> Association Study Locus Browser. <i>Movement Disorders</i> , 2020, 35, 2056-2067.	2.2	68
40	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	2.2	66
41	Accelerating Medicines Partnership: Parkinson's Disease. <i>Genetic Resource. Movement Disorders</i> , 2021, 36, 1795-1804.	2.2	60
42	Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1046-1054.	0.9	59
43	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020, 35, 774-780.	2.2	57
44	Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease. <i>Human Molecular Genetics</i> , 2019, 28, 3244-3254.	1.4	56
45	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Neuron</i> , 2021, 109, 448-460.e4.	3.8	56
46	Altered α -synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. <i>Trends in Neurosciences</i> , 2005, 28, 416-421.	4.2	50
47	A comprehensive analysis of <i>SNCA</i>-related genetic risk in sporadic parkinson disease. <i>Annals of Neurology</i> , 2018, 84, 117-129.	2.8	50
48	The Parkinson's Disease Mendelian Randomization Research Portal. <i>Movement Disorders</i> , 2019, 34, 1864-1872.	2.2	50
49	LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	49
50	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020, 35, 833-844.	2.2	48
51	Transcriptomic profiling of the human brain reveals that altered synaptic gene expression is associated with chronological aging. <i>Scientific Reports</i> , 2017, 7, 16890.	1.6	47
52	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	2.2	47
53	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1236.	4.5	46
54	Multi-modality machine learning predicting Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 35.	2.5	44

#	ARTICLE	IF	CITATIONS
55	Fineâ€Mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. <i>Annals of Neurology</i> , 2020, 87, 584-598.	2.8	39
56	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinsonâ€™s disease. <i>Journal of Medical Genetics</i> , 2020, 57, 331-338.	1.5	36
57	Assessing the relationship between monoallelic <i>PRKN</i> mutations and Parkinsonâ€™s risk. <i>Human Molecular Genetics</i> , 2021, 30, 78-86.	1.4	36
58	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 35-42.	2.8	29
59	Head injury, potential interaction with genes, and risk for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 292-296.	1.1	27
60	Heterozygous <i>PRKN</i> mutations are common but do not increase the risk of Parkinsonâ€™s disease. <i>Brain</i> , 2022, 145, 2077-2091.	3.7	26
61	Genomeâ€wide association study of neocortical Lewyâ€related pathology. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 920-931.	1.7	25
62	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 267-282.	1.5	21
63	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. <i>Movement Disorders</i> , 2022, 37, 857-864.	2.2	15
64	The Parkinson's Disease <sc>DNA</sc> Variant Browser. <i>Movement Disorders</i> , 2021, 36, 1250-1258.	2.2	11
65	Genome-wide estimates of heritability and genetic correlations in essential tremor. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 262-267.	1.1	10
66	Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors. <i>Annals of Neurology</i> , 2022, 92, 270-278.	2.8	10
67	Juvenile onset Parkinsonism with â€pure nigralâ€degeneration and POLG1 mutation. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 83-85.	1.1	9
68	A population scale analysis of rare SNCA variation in the UK Biobank. <i>Neurobiology of Disease</i> , 2021, 148, 105182.	2.1	5
69	Parkinson disease and clathrin coat dynamics at synapses, why not?. <i>Movement Disorders</i> , 2017, 32, 1163-1163.	2.2	4
70	Assessment of Genetic Association Between Parkinson Disease and Bipolar Disorder. <i>JAMA Neurology</i> , 2020, 77, 1034.	4.5	4
71	X-linked recessive dystonia parkinsonism (XDP; Lubag; DYT3). <i>Advances in Neurology</i> , 2004, 94, 139-42.	0.8	3
72	Susceptibility genes in movement disorders. <i>Movement Disorders</i> , 2008, 23, 927-934.	2.2	2

#	ARTICLE	IF	CITATIONS
73	Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1164-1164.	2.2	2
74	Leucine rich repeat kinase knockout (<i>LRRK</i> KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 72-72.	2.2	2
75	Familiality in simple and complex disease. <i>Clinical Autonomic Research</i> , 2003, 13, 88-90.	1.4	1